Cerebrospinal fluid lactoperoxidase level is enhanced in idiopathic Parkinson’s disease, and correlates with levodopa equivalent daily dose

•Lactoperoxidase concentration is enhanced in the cerebrospinal fluid in parkinsonian patients.•Lactoperoxidase in the cerebrospinal fluid holds promise as biomarker of Parkinsońs disease.•High levodopa equivalent daily doses attenuate elevated lactoperoxidase concentration in the cerebrospinal fluid.•High levodopa equivalent daily doses induce motor complications in patients. Lactoperoxidase (LPO) is proposed to play a role in the pathogenesis of Parkinson’s disease (PD). This enzyme has been reported to be enhanced in the cerebrospinal fluid (CSF) in parkinsonian patients. The objective was to look at the relationship of LPO in the CSF and serum with clinical features of idiopathic PD. LPO concentration was analyzed through ELISA techniques. Correlation of CSF or serum LPO and MDS-UPDRS, dopaminergic medication, and other clinical parameters was examined. The findings revealed that LPO concentration in the CSF, not serum, was found to be elevated in patients with PD relative to controls (p